FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Cognitive

Semax 5mg

5mg nootropic ACTH-analogue research peptide

From€39.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-SEM-5MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why Semax Fascinates Researchers

Semax is a synthetic heptapeptide analogue of the ACTH(4-10) fragment — the core behaviorally active sequence of adrenocorticotropic hormone — engineered for enhanced stability and CNS activity. Unlike the parent ACTH molecule, Semax does not bind melanocortin receptors or stimulate adrenocortical steroidogenesis; its biological activities are exclusively neurotrophin-mediated and neuroprotective in character.

ACTH(4-10) Analogue & Structural Architecture

The ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) was identified during early structure-activity studies of ACTH as the minimal sequence responsible for the hormone's behavioural and cognitive effects. These effects are independent of the melanocortin receptor binding and adrenal steroidogenic activity mediated by the full ACTH molecule. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) replicates this sequence with enhanced conformational stability conferred by its cyclic C-terminal Pro-Gly-Pro motif, providing improved resistance to aminopeptidase degradation and a longer pharmacokinetically effective window than the native fragment. The compound was developed at the Institute of Molecular Genetics, Moscow, as part of a programme investigating CNS-active peptides derived from pituitary hormone sequences.

BDNF/NGF Upregulation & Neuroprotection

The most extensively studied pharmacological property of Semax concerns its capacity to upregulate neurotrophin expression in brain tissue. Multiple rodent studies document increases in BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and their respective receptor systems (TrkB, TrkA) following Semax administration, with particularly robust effects in hippocampus, striatum, and frontal cortex. These neurotrophin responses are proposed as the mechanistic basis for Semax's documented neuroprotective effects in ischaemia models, where pre- or post-administration of Semax reduces infarct volume, attenuates glutamate excitotoxicity, and improves functional recovery metrics relative to untreated controls. The compound's activity in oxidative stress models further supports a neurotrophin-mediated neuroprotective mechanism.

Cognitive Research & Monoaminergic Systems

Semax demonstrates consistent effects on learning and memory task performance across multiple rodent paradigms including Morris water maze, passive avoidance, and operant conditioning protocols. Neurochemical studies document modulation of dopamine and serotonin systems — including altered catecholamine turnover in prefrontal cortical regions and hippocampal monoamine profiles. These effects are consistent with the compound's proposed activity as a neuropeptide that amplifies neurotrophin-dependent synaptic plasticity, with downstream consequences for monoaminergic neurotransmission. Semax has also been investigated in models of attention-deficit research and stress-induced cognitive impairment, where its neurotrophin-upregulating properties may counteract stress-related BDNF suppression.

This content is for informational purposes only and reflects the state of preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for Semax 5mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting Semax investigation.

[01]
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006) — Neuroscience Letters

“Semax, an analog of ACTH(4-7), regulates expression and activities of neurotrophin receptors in the rat basal forebrain”

Mechanistic study establishing Semax's capacity to upregulate TrkA and TrkB neurotrophin receptor expression and activity in rat basal forebrain. Authors document increased NGF and BDNF receptor levels alongside enhanced neurotrophin-mediated signalling, providing a molecular framework for Semax's cognitive and neuroprotective effects observed in behavioural models.

View on PubMed
[02]
Glazova MV, Manchenko DM, Volodina MA, et al. (2016) — Neuropeptides

“Semax, a synthetic analogue of ACTH(4-10), attenuates the development of opiate dependence”

Investigation of Semax's effects on opiate dependence development in rodent models, demonstrating modulation of dopaminergic reward circuitry. The study documents attenuation of morphine-induced conditioned place preference and withdrawal symptoms, consistent with Semax's reported effects on striatal dopamine turnover and mesolimbic pathway neuroplasticity.

View on PubMed
[03]
Agapova TY, Agniullin YV, Shram SI, et al. (2007) — Bulletin of Experimental Biology and Medicine

“Effect of Semax on the expression of BDNF and its receptor TrkB in rat brain structures under conditions of emotional stress”

Study examining Semax's effects on stress-induced suppression of BDNF and TrkB expression in rodent brain. Semax administration partially reversed stress-induced downregulation of hippocampal BDNF and its receptor, providing mechanistic evidence for Semax as a neuropeptide that counteracts stress-related neurotrophin depletion — relevant to cognitive impairment in chronic stress models.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about Semax.

Same Category

Similar Compounds

Other Cognitive research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.